Sarepta Therapeutics, Inc. $SRPT Shares Sold by LPL Financial LLC

LPL Financial LLC decreased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 18.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,698 shares of the biotechnology company’s stock after selling 9,740 shares during the period. LPL Financial LLC’s holdings in Sarepta Therapeutics were worth $2,789,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. EP Wealth Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 2.2% in the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock valued at $606,000 after purchasing an additional 105 shares during the period. Virtus ETF Advisers LLC increased its holdings in Sarepta Therapeutics by 6.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company’s stock valued at $342,000 after acquiring an additional 174 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Sarepta Therapeutics by 4.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company’s stock valued at $571,000 after acquiring an additional 218 shares in the last quarter. UMB Bank n.a. increased its holdings in Sarepta Therapeutics by 53.0% during the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 276 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its holdings in Sarepta Therapeutics by 2.6% during the 1st quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company’s stock valued at $713,000 after acquiring an additional 285 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 7.4%

Shares of SRPT stock opened at $21.81 on Monday. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of -25.07 and a beta of 0.46. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $144.22. The firm’s 50 day moving average price is $19.75 and its two-hundred day moving average price is $53.11.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to analysts’ expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. Sarepta Therapeutics’s revenue was up 68.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.07 earnings per share. On average, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Ratings Changes

SRPT has been the subject of several recent research reports. TD Cowen downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $24.00 target price for the company. in a report on Wednesday, June 18th. Wolfe Research initiated coverage on shares of Sarepta Therapeutics in a report on Tuesday, June 17th. They set a “peer perform” rating for the company. Bank of America restated an “underperform” rating on shares of Sarepta Therapeutics in a report on Wednesday, July 23rd. The Goldman Sachs Group raised their target price on shares of Sarepta Therapeutics to $19.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Finally, William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. Six research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $43.63.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.